Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4202981
Max Phase: Preclinical
Molecular Formula: C36H42Cl2N4O8S
Molecular Weight: 761.72
Molecule Type: Small molecule
Associated Items:
ID: ALA4202981
Max Phase: Preclinical
Molecular Formula: C36H42Cl2N4O8S
Molecular Weight: 761.72
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)c1ccc(COc2cc(Cl)c(CN3CSC[C@H]3C(=O)N3CCN(C4CC4)c4ccccc43)cc2Cl)cc1
Standard InChI: InChI=1S/C36H42Cl2N4O8S/c37-25-14-32(50-18-21-5-7-22(8-6-21)35(48)39-15-30(44)33(46)34(47)31(45)17-43)26(38)13-23(25)16-40-20-51-19-29(40)36(49)42-12-11-41(24-9-10-24)27-3-1-2-4-28(27)42/h1-8,13-14,24,29-31,33-34,43-47H,9-12,15-20H2,(H,39,48)/t29-,30-,31+,33+,34+/m0/s1
Standard InChI Key: VQICVPORQPLTMV-IKVATAHOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 761.72 | Molecular Weight (Monoisotopic): 760.2100 | AlogP: 2.63 | #Rotatable Bonds: 14 |
Polar Surface Area: 166.27 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 12 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.64 | CX Basic pKa: 3.40 | CX LogP: 2.21 | CX LogD: 2.21 |
Aromatic Rings: 3 | Heavy Atoms: 51 | QED Weighted: 0.14 | Np Likeness Score: -0.68 |
1. Chen T, Reich NW, Bell N, Finn PD, Rodriguez D, Kohler J, Kozuka K, He L, Spencer AG, Charmot D, Navre M, Carreras CW, Koo-McCoy S, Tabora J, Caldwell JS, Jacobs JW, Lewis JG.. (2018) Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5)., 61 (17): [PMID:30141927] [10.1021/acs.jmedchem.8b00308] |
Source(1):